Britain has signed a deal for the supply of up to 60 million doses of a potential coronavirus vaccine developed by Sanofi and GlaxoSmithKline (GSK). Human clinical studies of the vaccine will begin in September followed by a phase 3 study in December. The government has now signed deals for four different types of potential coronavirus vaccines and a total of 250 million doses. If the Sanofi/GSK treatment proves successful, the UK could begin vaccinating priority groups such as frontline health and social care workers and those at increased risk from coronavirus. The vaccinations would take place as early as the first half of next year, the Department for Business, Energy & Industrial Strategy (BEIS) said. ...read more...